← Markets

Fresenius Medical Care AG & Co. KGaA

FMS · NYSE

Market closed$24.11$0.020000 (+0.08%)After hours $24.11 · 0.00%

Key statistics

Previous close$24.09
Open$24.19
Day high$24.36
Day low$24.06
52-week high$27.64
52-week low$20.02
Market cap12.95B
Volume500.09K
Average volume745.02K
P/E ratio9.57
Forward P/E—
EPS2.52
Dividend yield+3.53%

Market context

Why it moved

FMS edged slightly higher amid broadly stable market conditions, with no major company-specific catalysts, as improving investor sentiment and easing macroeconomic concerns provided modest support across equities.

FacebookFacebookAgriviNhFacebook

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Fresenius Medical Care shares closed essentially flat amid a mixed backdrop for the broader healthcare sector. The sector is navigating significant headwinds from ACA and Medicaid enrollment declines — UnitedHealth reported losing 525,000 Medicaid members due to new work requirements, while HCA flagged a $1–$1.2 billion hit from ACA market changes — pressures that ripple across care facilities. Partially offsetting sentiment, UBS upgraded its outlook on healthcare as a key allocation theme, and UnitedHealth's strong Q2 beat on medical cost ratios lifted managed care peers.

0.083

July 16, 2026Fresenius Medical Care closed essentially flat amid a broad healthcare sector rally driven by UnitedHealth Group's blowout Q2 earnings, which saw UNH surge over 4.6% after beating estimates and raising full-year guidance. While managed care and health services peers benefited significantly from the improved medical cost ratio data and easing utilization concerns, the dialysis-focused care provider saw muted spillover, likely reflecting its distinct business model exposure to reimbursement dynamics rather than insurance utilization trends. UBS has flagged healthcare as a key sector allocation focus, citing improving earnings revisions and a stabilizing regulatory environment.

0.1247

July 10, 2026Fresenius Medical Care closed modestly higher as investors weigh the company's ongoing FME25+ transformation progress against a cautious near-term outlook. A recent Zacks analysis highlighted improving margins—with EUR 50M in quarterly savings and 10% operating income growth—but flagged a looming TDAPA reimbursement headwind of ~EUR 80M expected in H2 2026, alongside persistent U.S. dialysis volume weakness. With Q2 earnings season approaching and the broader healthcare sector trading at a slight premium after a strong 9.47% Q1 rally, investor attention is sharpening on reimbursement risk and volume recovery.

0.4601

July 10, 2026Fresenius Medical Care closed essentially flat amid a broadly resilient healthcare sector, even as macro headwinds from renewed U.S.-Iran tensions drove oil prices sharply higher and weighed on global equities. The company continues to balance improving FME25+ transformation savings and margin expansion against near-term risks including potential TDAPA reimbursement headwinds in H2 2026 and persistent U.S. dialysis volume pressure. In after-hours trading, shares slipped further, with investors also weighing a Zacks Hold rating and a consensus earnings estimate implying a ~7% EPS decline for 2026.

-0.1253

July 8, 2026Fresenius Medical Care closed modestly lower as broader market risk-off sentiment weighed on equities following Trump's declaration that the Iran interim deal was "over," sending oil surging 5%+ and triggering a global selloff. A Zacks analysis published today highlighted reasons to retain FMS shares, noting improving profitability and transformation strategy momentum, though analyst consensus remains cautious with a "Strong Sell" average rating. The healthcare sector posted its second consecutive week of market-leading outperformance, with XLV up over 5% last week, but FMS lagged as geopolitical macro headwinds and a bearish analyst skew — including Morgan Stanley's "underweight" and a recent Zacks downgrade — kept sentiment subdued despite a raised annual dividend and steady institutional accumulation.

-1.0744

July 8, 2026Fresenius Medical Care gained 2.50%, riding a broader healthcare sector rally that has made healthcare the best-performing S&P 500 sector for two consecutive weeks, with XLV up over 5% last week alone. Institutional interest in FMS has been building, with multiple funds — including Moran Wealth Management (+31.5%) and Ritholtz Wealth Management (+252.7%) — increasing stakes in Q1, even as analyst consensus remains cautious at 'Strong Sell' with a $28 price target. The company recently raised its annual dividend to $0.8716/share and posted Q1 EPS of $1.05 on $5.34B in revenue, with full-year EPS estimates of $2.24 implying a P/E near 11x.

2.4989

July 6, 2026Fresenius Medical Care edged up modestly during the regular session but slipped in after-hours trading, as broader healthcare sector weakness weighed on sentiment alongside a largely bearish analyst consensus — currently rated 'Strong Sell' with five sell ratings among covering analysts. Institutional interest has been mixed: while several funds increased stakes in Q1, analysts project full-year EPS of $2.24 against a backdrop of sector-wide headwinds. Parent company Fresenius SE continues to emphasize healthcare services expansion and efficiency, though investors appear cautious given the stock's elevated P/E/G ratio and limited near-term catalysts ahead of the next earnings cycle.

0.34

July 3, 2026Fresenius Medical Care rose nearly 3% on strong volume — roughly 60% above its daily average — aided by a broader healthcare sector tailwind after Universal Health Services surged 5.3% following a favorable Medicare reimbursement development from the Centers for Medicare. The kidney care giant also saw institutional support, with Pzena Investment Management disclosing a 2.0% increase in its stake to over 15 million shares. Despite a consensus 'Strong Sell' analyst rating and an average price target of $28.00, the stock's low P/E of ~12x and a raised annual dividend signal continued value interest among contrarian institutional buyers.

2.9309

Finimize · July 17, 2026Fresenius Medical Care’s Big Dialysis Rollout Meets A Tough Roadad-hoc-news.de · July 17, 2026FMC stock trades steady as Fresenius Medical Care refines focus and marginswww.marketscreener.com · July 17, 2026FMC FRESENIUS MEDICAL CARE AG : JP Morgan reiterates its Sell ratingMoomoo · July 16, 2026Fresenius Medical Care Started at Mkt Perform by BernsteinTradingView · July 2, 2026DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now?PR Newswire · June 3, 2026Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysisInvesting.com · May 5, 2026Earnings call transcript: Fresenius Medical Care Q1 2026 beats EPS expectationsReuters · February 24, 2026Fresenius Medical Care's meek 2026 guidance sends shares falling
Mt Newswire · May 28, 2026Fresenius Medical Care Launches First Tranche of Share Repurchase Program
Mt Newswire · May 26, 2026Fresenius Medical Care Plans $1.16 Billion Share Buyback Program
Benzinga · May 26, 2026Fresenius Medical Care Announces ~€1B Stock Buyback
Mt Newswire · May 20, 2026Fresenius Medical Care Reappoints Martin Fischer as CFO
Mt Newswire · May 6, 2026Research Alert: CFRA Keeps Sell Opinion On Ads Of Fresenius Medical Care
Benzinga · May 5, 2026Fresenius Medical Care Affirms FY2026 Sales Guidance of $23.764B vs $22.870B Est
Benzinga · May 5, 2026Fresenius Medical Care Q1 Adj. EPS $0.53 Misses $0.59 Estimate, Sales $5.401B Miss $5.720B Estimate
Mt Newswire · May 5, 2026Fresenius Medical Care Q1 Earnings, Revenue Fall; Reiterates 2026 Revenue Outlook

Peers

S&P 500SPX · $7,457.69-1.01%DaVita Inc.DVA · $236.97+1.26%Quest Diagnostics IncorporatedDGX · $210.68+0.61%Labcorp Holdings Inc.LH · $283.36+0.50%Chemed CorporationCHE · $510.03+1.70%Baxter International Inc.BAX · $22.61-3.17%Becton, Dickinson and CompanyBDX · $158.17-1.10%Terumo Corporation4543.T · ¥2,267.50+2.74%HCA Healthcare, Inc.HCA · $371.18-3.77%Tenet Healthcare CorporationTHC · $194.91-2.15%Universal Health Services, Inc.UHS · $151.16-1.55%Fresenius SE & Co. KGaAFSNUY · $11.99-0.66%